Sequenom, Roche diagnostic news

The U.S. Court of Appeals for the Federal Circuit (CAFC) upheld a lower court judgment that U.S. Patent No. 6,258,540 covering prenatal diagnosis using nucleic acid analysis used in Sequenom’s MaterniT21 Plus laboratory-developed test (LDT) is invalid. Ariosa Diagnostics Inc., which Roche acquired, filed suit against Sequenom in 2011 arguing that its Harmony Prenatal Test does not infringe patent ‘540. In 2013, a judge in the U.S. District Court for the Northern District of California again ruled that the patent was invalid (see BioCentury, Nov. 4, 2013 & Jan. 5, 2015). ...